As the overall prognosis and treatment response rate to standard chemotherapy for acute myeloid leukemia (AML) remains poor in the older adult population, there is a need for more effective therapeutic agents with lower toxicity profi les that can be offered to these patients. Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal antibody that was approved by the US Food and Drug Administration for use as monotherapy in patients 60 years of age and older with relapsed AML. GO consists of a humanized anti-CD33 antibody (hP67.6) which is linked to N-acetyl-γ calicheamicin 1,2-dimethyl hydrazine dichloride. Once the antibody attaches to the surface antigen, it is rapidly internalized. Calicheamicin, a potent enediyne, is subsequently released and acts as a cytotoxic anti-tumor agent. In this population, GO has an acceptable toxicity and yields response rates approaching 30%. The effi cacy of GO as monotherapy and in combination therapy for treatment of both de novo and relapsed AML continues to be investigated.
Background -acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common type of acute leukemia occurring in adults. There will be an estimated 13,290 new diagnoses in the United States in 2008, with a yearly, age-adjusted incidence rate of 3.6 per 100,000 people. 1 The median age at diagnosis is approximately 67 years, and the incidence is rising, particularly in the "very old" (patients in their 8th and 9th decades of life), likely related to the aging population as a whole. Thus, the majority of AML is seen in older adults.
Initial treatment has not changed signifi cantly over the last 30 years. Standard regimens use cytarabine combined with anthracyclines or anthracenediones for remission induction, followed by cytarabine, alone or in combination, for post-remission therapy. Although there has been little change in chemotherapy regimen, supportive pharmacologic care (including antiemetics, and antibiotics) has improved significantly and has made this chemotherapy more tolerable. The rate of relapse, however, remains high, and the overall outcome in older adult populations is poor. Conventional chemotherapy regimens induce complete remission (CR) in 65% to 85% of patients younger than 60 years of age. [2] [3] [4] [5] [6] [7] [8] Of those achieving a CR, only 30% to 40% can expect long-term disease-free survival (DFS). In older adults (Ն 60 years of age), results are even more dismal, with CR achievable in 40% to 55% of patients. Of those who do achieve a CR, only 10% to 20% are still alive 3 years out from diagnosis. 4, [9] [10] [11] This low chance of durable remission comes at a price of high treatment-related mortality (20% or higher compared to less than 10% in the younger adult population). A number of studies have explored more intensive up-front chemotherapy, addition of cytotoxic drugs, and even extended maintenance therapy, without demonstrable improvement in survival outcomes. [12] [13] [14] [15] Thus, for almost all older AML patients, therapy for relapsed disease will be a consideration.
Pathobiology of AML in older adults
Why the high relapse rate in older adults? As advances in molecular biology and genetics continue to develop, AML in the older adult population is increasingly recognized as having distinct biological features and disease characteristics from AML in younger adults.
In the older adult population, AML is more likely to arise from proximal bone marrow stem cell disorders (such as MDS) and with leukemia-specifi c abnormalities in more than one hematopoeitic cell lineage. Approximately 30% of older patients with de novo AML actually have evidence of trilineage myelodysplasia. 17 Having an antecedent hematologic disorder is associated with poor response to chemotherapy, prolonged periods of cytopenia, lower CR and shorter duration of CR.
In older adults, there tends to be a higher incidence of poor-risk cytogenetic abnormalities, such as abnormalities of chromosomes 5, 7, 8, or complex cytogenetics, and multiple comorbidities. They are also less likely to have good-risk cytogenetic fi ndings, such as balanced, core-binding factor abnormalities, including t(8; 21); inv (16) and t(16; 16), involving CBFB-MYH11 chimeric product; and the PML-RARa mutation t(15; 17). [18] [19] [20] [21] [22] Whether newly identifi ed molecular lesions such as the FMS-related tyrosine kinase 3 gene internal transmembrane duplications (FLT3 ITDs) and mutations of the nucleophosmin gene (NPM1) play a role in the older adult population of AML patients has yet to be determined, though preliminary data indicate these abnormalities may have even greater prognostic potential than the core binding factor abnormalities. Ultimately, however, older age seems to predict for higher rates of relapse and signifi cantly shorter OS. 23 Secondary AML, which is less responsive to chemotherapy, also is more common in this age group, comprising between 25% and 50% of cases, compared to Ͻ10% in younger adults. Secondary AML is associated with poorer outcomes. 2, 20, 24 Finally, AML in the older adult population appears to be intrinsically more diffi cult to treat, with a higher incidence of resistance to conventional chemotherapy. This is mediated by greater expression of genes that confer drug resistance, such as MDR1, the P-glycoprotein (gp170) chemotherapy effl ux pump, present in one study in 71% of myeloblasts in older adults, compared to only 35% of blasts in younger AML patients.
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Choosing therapy of older adults with AML The diffi cult decision
Because conventional chemotherapy has such dismal outcomes in the older adult population and the treatment-related mortality and morbidity are so high, the decision of therapy in older adults can be a complicated and diffi cult process, and as much as possible intensive therapy should be directed to specifi c molecular abnormalities, or avoided with particularly poor risk characteristics. One study explored the effect of time from diagnosis of AML to treatment initiation on CR and OS in over 1300 AML patients. The results showed that delaying therapy in older patients had no impact on these survival outcomes. 25 Thus, older patients may benefi t from waiting for the results of additional testing to return, allowing enrollment into studies that account for cytogenetic fi ndings or that target molecular therapies.
Although indirect data support the use of intensive chemotherapy in older patients (60 years or older), most will derive little benefi t from this approach. Only one randomized study, reported two decades ago, has ever shown a survival advantage of remission induction therapy (with daunorubicin, vincristine, and cytarabine) as compared to best supportive care. This trial noted a signifi cant median survival benefi t of only 10 weeks for patients receiving remission induction therapy. 26 A more recent case-control study showed a survival advantage for giving intensive chemotherapy compared to best supportive care or low-dose approaches of 197 days vs 53 days (hazard ration [HR] 1.88, p = 0.01). 27 Because of high treatment-related mortality and poor outcomes, many older patients choose less aggressive therapy, often at the recommendation of their physicians. In a study by Ferrara, et al questionnaires were sent to 32 hematologic institutions involved in the Gruppo Italiano per le Malattie Ematolgiche dell'Adulto (GIMEMA) group. The purpose of the study was to assess the various factors that infl uence therapeutic choice in the older population with relapsed AML. The most frequent factor found to infl uence therapeutic choice was performance status. Other additional factors included age Ͼ 70 years, duration of CR1 (Ͼ or Ͻ12 months), concomitant disease requiring specifi c treatment. It is interesting to note that other prognostic factors such as cytogenetics, serum LDH, previous MDS or white blood cell count were not considered as heavily in this older population. 28 In older patients who are not fi t for aggressive care, Burnett et al have also demonstrated that low-dose ara-C treatment was superior to best supportive care and hydroxyurea in achieving CR.
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Therapy of relapsed AML in older adults
In the younger adult population, in the setting of relapsed disease, the goal is cure. Intensive, cytarabine-based chemotherapy salvage regimens with subsequent allogeneic hematopoietic stem cell transplantation remain preferred treatments. These approaches are likely to be too toxic in older adults with relapsed AML, in whom the goals of therapy can no longer be curative. In those older patients who are fi t enough and want to continue with treatment, according to National Comprehensive Cancer Network (NCCN) guidelines (for patients who are 60 years of age and older) the recommendations for salvage therapy are enrollment in clinical trials, repetition of initial induction chemotherapy regimen (if the patient has already enjoyed a durable remission from that therapy), or gemtuzumab ozogamicin.
Gemtuzumab ozogamicin
Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal antibody that is conjugated to a cytotoxic agent, calicheamicin. It was approved by the FDA in May 2000 for use as single-agent therapy in elderly patients (patients Ն 60 years old) with fi rst-recurrence CD33
+ AML who are not candidates for standard therapy. The approved dose is 9 mg/m 2 intravenously (given on days 1 and 15).
The CD33 antigen
The CD33 antigen is a transmembrane cell-surface glycoprotein (of unknown function) that is specifi c for myeloid cells.
It is a member of the sialic acid-binding immunoglobulinlike lectin (siglec) family. It is found on both mature and immature myeloid cells. It is found on erythroid, megakaryocytic, and multipotent progenitors. It is not present on normal pluripotent hematopoietic stems cells. Because it is absent on normal hematopoietic stem cells and has little expression in non-hematopoietic tissue, the CD33 + antigen is a reasonable target for monoclonal antibodies against AML. CD33 is expressed on approximately 90% of myeloblasts in patients with AML, as defi ned by the presence of antigen on greater than 20% leukemic blasts. It is also found on leukemic blasts in a majority of patients with MDS. When CD33 + intensity was compared in patients with AML, it was found to be signifi cantly higher in patients Ͻ60 years of age compared to those who were older. However, levels of CD33 + intensity did not correlate with cytogenetics, response to therapy, or overall survival.
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GO pharmacology
GO is a humanized IgG4 anti-CD33 monoclonal antibody (hP67.6) conjugated to N-acetyl-γ calicheamicin dimethyl hydrazide, a derivative of calicheamicin.
The IgG4 isotype was chosen because it has the longest circulating half-life of all isotypes and is the least likely to participate in immune-mediated mechanisms like complement fi xation and antibody-dependent cellular toxicity. The hP67.6 antibody is non-cytotoxic by itself. Calicheamicin is a naturally occurring enediyne antibiotic isolated from actinomycete Micromonospora echinospora calichensis. Enediyne antibiotics are unique reactive compounds; once aromatized, they produce cytotoxic biradicals that cause phophodiester bond DNA breakage. This conjugation allows a favorable balance between hydrolytic stability in physiological buffers (pH 7.4) and effi cient drug release at pH of lysosomes (pH 4).
GO is internalized rapidly after infusion. The endocytosed anti-CD33 complexes translocate to lysosomes where the acidic environment causes release of the calicheamicin derivative. A reactive intermediate of the caclicheamicin is formed through reduction by glutathione which causes double-strand breaks in DNA.
Gender and age do not appear to effect GO pharmacokinetics. There are no signifi cant differences between younger and older patients in terms of maximum concentration, time to maximum concentration, area under the curve, clearance, or volume of distribution of GO.
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GO as single-agent therapy in older patients with relapsed AML
In a phase 1 study by Sievers et al GO as a single agent was used to treat 40 patients with refractory or relapsed AML. The doses ranged from 0.25 to 9 mg/m 2 . Patients were included in the study if they had good performance status, a white blood cell count Ͻ 30 × 10 9 /L, and no evidence of renal or liver dysfunction. Of these patients, 18 had undergone prior allogeneic stem cell transplant. Twenty percent achieved a reduction in marrow blast count, with less than 5% blasts at morphologic exam. Toxicities were mostly infusion-related fevers and chills, and myelosuppression. Approximately 20% of patients also developed mild elevations of liver transaminases. 32 The study above then led to 3 open-label multicenter phase II trials, with GO given at a dose of 9 mg/m 2 (see Table 1 ). Because the study designs, endpoints, patient demographics, and dosing schedules were similar, the patients were pooled together to attain a larger effi cacy population. From reports in 2001 by Sievers et al 33 and by Larson et al in 2005, 34 a total of 277 AML patients were enrolled. These patients were all in fi rst relapse and had evidence of CD33 + AML blasts.
The median age was 61 years old. The primary end point was the number of patients attaining CR, and secondary end points were the rates of complete remission with persistent thrombocytopenia (CRp), relapse-free survival (RFS), overall survival (OS), and time to platelet-and time to ANC recovery. The overall response rate was 26% (13% achieved CR and 13% achieved CRp), with a median time to remission of 60 days. Interestingly, there were no differences in response rates among patients stratifi ed by age or cytogenetic abnormalities. The median RFS was 6.4 months for patients who achieved CR and 4.5 months for patients who achieved a CRp. Toxicities included infusion-related fevers and chills, myelosuppression, and about 30% of patients developed treatment-related infections and/or elevations of bilirubin and transaminases.
In a meta-analysis by Leopold et al, GO as monotherapy was compared to high-dose cytosine arabinoside (HiDAC) in patients with fi rst-relapse AML. The outcome of 128 patients historically treated with HiDAC-containing chemotherapy regimens were compared to 128 patients (enrolled in multiple phase II trials) who were treated with GO (9 mg/m 2 on days 1 and 15). The median age of patients receiving GO was signifi cantly higher (60 years of age) than those treated with HiDAC (50 years of age). Of those receiving GO, 41% of patients achieved a CR or CRp. If the fi rst remission was between 10 and 19 months, there were no differences between the two groups for remission duration following treatment. However, if the fi rst remission duration was 3 to 10 months, then patients treated with GO had higher remission duration following treatment. Interestingly, there was no statistical difference between overall remission rates with GO or HiDAC containing chemotherapy regimens between the different cytogenetic groups. Interestingly, the analysis revealed that early death rate occurred with HiDAC if age was less than 45 years, whereas lower early death rate resulted from GO therapy in patients who were greater than 75 years of age. 35 It is important to note that this was not a randomized study and the median ages of these two groups were signifi cantly different, likely refl ecting that few older patients are considered candidates for HiDAC.
Toxicity
GO is generally tolerated well. The most common infusionrelated reactions include chills, fevers, and hypotension that can occur acutely. In the pivotal phase II studies which led to FDA-approval of GO, Larson et al analyzed the effi cacy and safety of GO and found that the incidence of Grade 3 or 4 infusion-related events included fevers (6%), chills (8%), hypotension (4%), nausea (3%), and hypertension (2%). 34 The hypotension occurred several hours after completion of infusion and was reversible with intravenous fl uid administration. The incidence of infusion-related events was lower on repeat administration. Preventive therapy with corticosteroids and acetaminophen and diphenhydramine were effective in reducing infusion related toxicities. There was no difference in incidence of infusion-related reactions between younger and older patients.
Myelosuppression was seen in the majority of patients. In phase II trials, grade 3 or 4 neutropenia was observed in 98% of patients. However, the incidence of grade 3 or 4 sepsis (17%) and pneumonia (8%) was lower than would be expected. There was no signifi cant difference in the incidence of infections or in the median time to absolute neutrophil recovery (to 500/μL) between younger and older patients. Despite the observation of grade 3 or 4 thrombocytopenia in 99% of patients, the overall incidence of grade 3 or 4 bleeding events was only 13%. In younger and older patients who achieved CR, platelet count to 25,000/μL occurred in a median of 35 days and 38 days, respectively. In younger and older patients who achieved a CRp, platelet count to 25,000/μL occurred in 39 days and 72 days, respectively. Elevations in hepatic transaminases and bilirubin were also observed. These were mostly transient events. Grade 3 or 4 hyperbilirubinemia occurred in 29% of patients, elevations in hepatic aspartate aminotransferase occurred in 18%, and elevations in alanine amino-trasnsferase in 9%. Veno-occlusive disease (VOD) occurred in 16 (5%) patients, eight patients died of this condition. Patients who undergo subsequent myeloablative HSCT were found to have higher incidence of developing VOD. There was no signifi cant difference in incidence of hepatotoxicity between younger and older patients. 34 
GO as combination therapy in older adults with relapsed AML
Several trials have evaluated effi cacy of GO in combination with cytotoxic chemotherapy as fi rst-line therapy, and for treating refractory/relapsed AML (see Table 2 ). GO has been studied in combination with cytosine arabinoside (ara-C) alone; idarubicin and ara-C; liposome-encapsulated daunorubicin, ara-C, and cyclosporine; fl udarabine, ara-C and cyclosporine; and others. [36] [37] [38] [39] [40] The results have been variable, likely refl ecting the heterogeneity of these diseases.
In a phase II study by Tsimberidou et al the effi cacy of GO used in combination with fl udarabine, Ara-C, and cyclosporine (MFAC) in patients with relapsed or refractory AML was investigated. The median age was 53 years, with 11 of the patients older than 60 years of age. Thirty-two patients were included in this study (34% with refractory disease, 66% with relapsed AML). Nine (28%) patients achieved CR and 2 (6%) achieved CRp. Of those achieving CR or CRp, 4 (36%) patients were 60 years or older. The median OS was 5.3 months. Signifi cant side effects were grade 3 or 4 hyperbilirubinemia (44%), grade 3 or 4 elevated tramsaminases (18%), and VOD (9%). 36 Stone et al in 2004, in a CALGB study, evaluated the effi cacy of treating patients with relapsed or refractory AML with high-dose ara-C (HiDAC) in combination with GO at different doses (9 or 4.5 mg/m 2 ). The median age was 64 years. In the initial cohort of patients treated with HiDAC 3.0 g/m 2 (over 3 hours daily for 5 days) and GO 9 mg/m 2 (on day 1) and 4.5 mg/m 2 (on day 8) signifi cant toxicity was seen; 8 of the 9 patients died during induction therapy. In the phase II study, 44 patients were treated with HiDAC 3.0 g/m 2 (over 3 hours daily for 5 days) and GO at 9 mg/m 2 (on day 7). Seven (19%) achieved CR and two (5%) achieved CRp. None of these patients developed VOD. 37 Recently, Doyen et al evaluated the efficacy of GO and cytarabine in older patients with relapsed or refractory AML. Fourteen patients were included in the study and the median age was 70 years. Seven patients had de novo AML and 7 had secondary AML. All patients received GO (6 mg/m 2 on day 1 and 4 mg/m 2 on day 8) and cytarabine (100 mg/m 2 /24 hours on days 1-7). Two patients achieved CR, one achieved CRp, and one achieved PR with an overall response rate of 28%. The median OS was 4.6 months. Treatment-related death occurred in 4 (28%) patients. 38 Fianchi et al evaluated the effi cacy of GO in combination with ara-C and G-CSF (G-AraMy regimen) in the treatment of elderly patients with poor-prognosis AML. Fifty-three patients, with either untreated or relapsed/primary refractory AML, were included in this study. The median age was 69 years. The OR rate was 57%. Twenty-three patients (43%) achieved CR and 1 patient (2%) achieved CRp. Eleven patients (21%) achieved PR and, following consolidation, 10 patients achieved CR. Median DFS was 8 months (range or 2-23 + months) and OS was 9 months (range 2-24 + months). The most common side effect was myelosuppression. This study is also interesting in that these responses were obtained without the use of anthracyclines, which can be especially toxic to older patients. Seven patients (13%) died during induction. The authors concluded that G-AraMy could be a useful treatment approach, with acceptable toxicity, for poor-risk elderly AML patients. 39 In a phase II study by Chevallier et al GO was combined with intermediate doses of ara-C and mitoxantrone (MIDAM regimen). Sixty-two patients were included in the study (18 patients with refractory disease and 44 patients with relapsed disease). The median age was 55.5 years, 22 patients were 60 years of age or older. The MIDAM regimen consisted of GO (9 mg/m 2 ) on day 4, cytarabine (1 g/m 2 ) every 12 hours on days 1 through 5, and mitoxantrone (12 mg/m 2 /day) on days 1 through 3. The median duration of follow-up was 26.5 months. The overall response rate was 63%; 31 (50%) patients achieved CR and 8 (13%) patients achieved CRp. Of those achieving CR or CRp, 15 (24%) were 60 years of age or older. Grade 3 to 4 hyperbilirubinemia occurred in 16% of patients and 3% developed VOD.
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GO as front-line therapy in older adults with AML
There are several studies that have evaluated the effi cacy of GO in untreated AML. A phase II trial evaluating the effi cacy of GO as monotherapy for induction, consolidation, and maintenance therapy was done by Nabhan et al in 2005. Twelve patients were included in the study. All were over the age of 65 years and none had received any prior treatment for AML. Standard doses of GO (9 mg/m 2 ) were used as induction therapy. For consolidation, GO (6 mg/m 2 ) was given 45 to 60 days after chemotherapy and following recovery of peripheral counts. For maintenance, GO (3 mg/m 2 ) was given every 4 weeks for 4 cycles. Three (27%) patients achieved CR. The toxicity profi le was acceptable, with myelosuppression being the most common adverse effect. Five of the patients had transient elevation of transaminases, but none had grade 3 or 4 hyperbilirubinemia. None of the patients developed VOD. 41 Another study by GIMEMA-European Organization for Research and Treatment of Cancer (EORTC) groups investigated the use of GO as single-agent therapy in induction therapy in elderly patients (AML-15B). Patients were eligible for the study if they were Ͼ75 years of age and had a World Health Organization performance score (PS) of 0-2, or an age between 61 and 75 years with a WHO PS Ͼ 2. Over 50% of these patients were over the age of 50 years and were deemed to be too frail for other therapy. Forty patients received GO (9 mg/m 2 ) in two doses given 2 weeks apart. Seven patients achieved either a CR or CRp (17%), 24 patients had resistant disease (60%), and 7 patients died during induction (17%). The median OS was 4.3 months; 1-year survival was 34%; and 2-year survival was 7%. Toxicities included myelosuppression (a majority of patients), and severe liver toxicity (4 patients, only 1 died of fatal VOD). From this study, it was concluded that GO given at this dose was too toxic for patients over the age of 75 years and dose-reduction should be strongly considered. 42 Estey et al evaluated GO with or without interleukin 11 (IL-11) compared to patients who had received idarubicin and continuous-infusion, high-dose cytarabine (IA). Fifty-one patients were included in the study and the median age was 72 years. Patients were randomized to received induction therapy with GO (9mg/m2 on days 1 and 8) with or without IL-11 (15 μg/kg on days 3-28). Two of 26 patients who received GO achieved CR. Nine of 25 patients who received GO and IL-11 achieved CR. This was compared to patients who had received IA. Patients who had received IA demonstrated higher CR rate and survival rates. 43 Clavio, et al evaluated the effi cacy of adding low-dose GO to fl udarabine, ara-C, and idarubicin (MY-FLAI regimen) in patients with newly diagnosed CD33 + AML. This was a prospective, multi-center trial in comparison with a historical cohort of patients who had received FLAI, without GO. Forty-six patients were treated with MY-FLAI and compared with a historical cohort of 47 patients (matched for age and cytogenetics) who received FLAI. The median age was 66 years. There was no signifi cant difference in CR rate between the groups. However, patients with de novo AML receiving GO had lower risk of relapse at 2 years (40% vs 80%, p = 0.01) and also demonstrated signifi cantly better overall survival (40% vs 14%, p = 0.02). A higher incidence of induction-related deaths were actually reported in the historical cohort of patients only receiving GO than compared to those who received the MY-FLAI regimen. This data suggested that adding GO might prolong DFS, particularly in patients with de novo AML, with acceptable toxicity. 44 In another phase II study, Nand et al reported on the use of a combination of hydroxyurea, azacitidine, and low-dose GO in elderly patients with untreated non-M3 AML and high-risk MDS. Twenty patients were enrolled in the study (17 patients had AML and 3 had MDS RAEB II). The median age was 76 years. The hydroxyurea was administered in order to reduce the white blood cell count to below 10,000/μL and allow for a lower GO dose (3 mg/m 2 ), in attempts to decrease toxicity. Eleven patients (55%) achieved a CR and 3 achieved Gemtuzumab ozogamicin for acute myeloid leukemia CRp (15%). The median DFS was 8 months and median OS was 10 months. Only 1 patient died early on due to disease progression. A majority of these patients were able to be treated in the outpatient setting.
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GO in older adults with APL
In patients with acute promyelocytic leukemia (APL), the addition of GO can produce molecular remission. APL blasts typically have high expressions of CD33 antigen and they also have low levels of P-glycoprotein (Pgp), which is a product of the MDR1 gene which is a known mediator of multidrug resistance. GO has been found to be highly effective in treating patients with APL in relapse, and is an active area of research to avoid the use of anthracyclines and cytarabine, a particularly appealing approach for the rare older adult with APL.
Lo-Coco et al evaluated GO as monotherapy for molecularly relapsed APL. Among 16 patients included in the study, 7 were older than 65 years of age. All patients had received prior therapy of ATRA and anthracycline-based therapy with cytarabine. All patients had demonstrated molecular relapse. These patients were treated with GO at 6 mg/m 2 on days 1 and 15. Fourteen (88%) patients responded and 7 (44%) of these patients remained in sustained molecular remission for median of 15 months. The estimated OS after fi rst GO treatment was 74% and molecular RFS was 43%. These results supported that GO could be used as monotherapy in patients with molecular relapse of APL. 46 Estey et al evaluated GO and all-trans retinoic acid (ATRA) in patients with previously untreated APL. GO was administered at a dose of 9 mg/m 2 on day 1 or day 5 of therapy. Nineteen patients were included in the study. Three patients also received idarubicin due to elevated white blood count Ͼ 30,000. Once CR was achieved, patients received 8 courses of GO (9 mg/m 2 every 4-5 weeks) and ATRA. If there was persistent or recurrent polymerase chain reaction (PCR) positivity, idarubicin was added to the maintenance regimen. Sixteen of the nineteen (84%) patients achieved CR. Fourteen of the 16 (88%) patients given GO and ATRA without idarubicin achieved CR. GO was well tolerated. These data suggested that GO could be effective therapy in patients with untreated APL. 47 Estey et al also investigated the effi cacy of GO combined with ATRA versus arsenic trioxide (ATO) and ATRA in patients with previously untreated APL. Among 44 patients with a median age of 49 years, 25 low-risk patients received ATO and ATRA for induction and, after achieving CR, received ATO plus ATRA without chemotherapy, while 19 high-risk patients received the identical treatment, but also received GO (9 mg/m 2 ) on day 1 of induction. Thirty-nine of the 44 patients achieved CR (24 of 25 in the low-risk, 15 of 19 in the high-risk). These results suggest that ATRA plus ATO may be an effective alternative to chemotherapy in patients with low-risk, previously untreated APL. It also suggests that ATRA plus ATO in combination with GO may be benefi cial in patients with high-risk, previously untreated APL. 48 Aribi et al investigated effi cacy of GO in combination with ATO and ATRA in patients with APL in fi rst relapse. Eight patients were enrolled in the study. Two (25%) patients were greater than 60 years. All patients had received previous treatment with ATRA as single-agent or in combination with other chemotherapy. Seven of these patients had hematologic relapse, and one had a molecular relapse. All patients achieved molecular CR. After a median follow-up of Ն36 months, 6 patients remained alive in CR and 2 patients died in CR. Of the 2 patients who died, 1 died due to complications of metastatic lung adenocarcinoma, and the other of sepsis. 49 Interestingly, in these patients with APL, the side effects were minimal and no cases of VOD have been reported. 49 
Resistance to GO
Sensitivity to GO and mechanisms of resistance to GO continue to be investigated. Initial in vitro investigations with GO were performed on 4 different human AML lines (KG1, THP-1, HL-60, and NB4) and subsequently in primary samples from patients with AML. GO was found to produce three different responses in AML cell lines: arrest in G2 phase of cell cycle followed by apoptosis, G2 arrest with little apoptosis, and resistance to high doses of GO. These different responses did not correlate with CD33 expression or multiple drug resistance (MDR) protein expression. 50 Recently, CD33 expression and P-glycoprotein (P-gp)-mediated drug effl ux have been shown to inversely correlate with response to GO. In this particular study by Water et al, CD33 expression and P-gp activity were found to be inversely correlated. Also, patients with lower P-gp activity demonstrated greater response to GO 51 However, it is possible that the effect against GO and calicheamicin occurs through other antiapoptotic mechanisms as well.
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Other approaches to relapsed AML in older adults
There are several other therapy approaches currently being investigated in older adults. Clofarabine, a purine nucleoside analog, is being studied as front-line therapy in older patients with AML. Decitabine and azacitidine are hypomethylating agents also being studied in de novo and relapsed AML. FLT3 ITD mutations, as mentioned before, have been found to be present in up to one-third of AML cell lines. These mutations result in unregulated cell proliferation. There are several oral FLT3 inhibitors that are currently under clinical investigation in relapsed/refractory AML and front-line in older patients who are considered "unfi t" for intensive chemotherapy. Tipifarnib, an oral farnesyltransferase inhibitor (FTI), has also been studied in older patients with refractory or relapsed AML. FTIs are selective inhibitors of intracellular farnesyltransferase, which is an enzyme that catalyzes transfer of farnesyl to cysteine terminal residue of various substrate proteins (including oncoprotein Ras and several others). These inhibitors subsequently inhibit cellular signaling transduction pathways and can potentially inhibit tumor growth.
Conclusions
GO is a humanized anti-CD33 monoclonal antibody therapy that has been shown to be affective and well tolerated in the older adult population. It has acceptable toxicity profi le; the main adverse effects include infusion-related events, severe myelosuppression, and hepatotoxicity (including VOD). GO is an important new anti-leukemic therapy and has promising effi cacy in both de novo and relapsed disease. It will be important to better defi ne the population of patients that would benefi t most from this targeted therapy. Also, the role of GO in monotherapy or in combination therapy regimens for the treatment of AML needs to be further investigated.
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